Ongoing Clinical Trials for Metastatic Lung Cancer
There is currently 1 ongoing clinical trial for metastatic lung cancer, specifically focusing on advanced non-small cell lung cancer. This trial is investigating a personalized cell therapy called ATL001, used alone and in combination with pembrolizumab, an existing cancer medication. The study is being conducted across multiple European countries to assess the safety and effectiveness of this new treatment approach.
Clinical trial locations
- France
- Germany
- Spain
Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer
This trial is investigating a new personalized treatment approach for patients with advanced non-small cell lung cancer that cannot be removed by surgery or has spread to other parts of the body. The study focuses on a cell therapy called ATL001, which uses specially designed immune cells (T cells) to recognize and attack cancer cells. Researchers are testing ATL001 both alone and in combination with pembrolizumab, an already approved cancer medication that helps the immune system detect and fight cancer cells.
Who can participate: The trial is open to adults between 18 and 75 years old who have advanced non-small cell lung cancer related to smoking. Participants must have received prior treatment with a medication called a PD-1/PD-L1 inhibitor and experienced either disease progression or stable disease after at least four doses. Patients need to have a life expectancy of at least 6 months and be in generally good health with adequate organ function based on blood tests. They must be physically fit enough to undergo tissue collection procedures and receive the study medications. Women of childbearing age must agree to use effective birth control during treatment and for up to 12 months afterward, while men must use birth control for at least 6 months after treatment.
Who cannot participate: Patients with other types of cancer besides non-small cell lung cancer are not eligible. Pregnant or breastfeeding women cannot join the study. Those who have allergic reactions to the study drugs, are taking certain medications that might interfere with the research, or have medical conditions that could complicate the trial are also excluded. Recent participation in another clinical trial may also affect eligibility.
What the trial involves: The study follows a multi-step process. After providing written consent and completing initial assessments including medical history review, physical examination, and blood tests, participants will have tumor tissue collected from accessible disease sites. This tissue is used to manufacture the personalized ATL001 therapy. Before receiving ATL001, patients undergo a preparation process called lymphodepletion, which involves taking medications (fludarabine and cyclophosphamide) to ready the body for treatment. ATL001 is then given through an intravenous infusion. Some participants will also receive pembrolizumab in combination with ATL001. Throughout the study, patients have regular follow-up appointments including imaging studies to monitor tumor size and overall health. The trial is expected to conclude by July 31, 2027.
Main goal: The primary focus is to assess the safety of ATL001 and how well patients tolerate this new treatment. Researchers will also measure how the cancer responds to therapy, including changes in tumor size and how long patients live without their disease getting worse. This research aims to provide new insights and potentially offer new treatment options for people with advanced non-small cell lung cancer.
Summary
Currently, there is one active clinical trial available for patients with metastatic lung cancer, specifically targeting advanced non-small cell lung cancer. This trial represents an innovative approach to cancer treatment, combining personalized cell therapy with established immunotherapy. The study is being conducted across three European countries—France, Germany, and Spain—providing access to this experimental treatment for eligible patients in multiple locations.
The trial focuses on two investigational approaches: ATL001, a personalized T-cell therapy designed to target specific cancer mutations, and its combination with pembrolizumab, an immune checkpoint inhibitor already used in cancer care. This reflects a broader trend in cancer research toward personalized medicine and combination therapies that work with the body’s immune system to fight disease.
Patients interested in this trial should discuss their eligibility with their healthcare provider, particularly if they have previously received PD-1/PD-L1 inhibitor treatment and meet the other health and age requirements outlined in the study criteria.
